Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven relapsed or refractory non-Hodgkin's lymphoma
• Scheduled to undergo high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan) with autologous peripheral blood mononuclear cell transplantation
• No metastatic disease involving the bone marrow
• PATIENT CHARACTERISTICS:
• Age:
• 17 to 65
• Performance status:
• ECOG 0 or 1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count greater than 1,500/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• No active hepatitis B or C
• Bilirubin less than 2.5 times normal\*
• SGOT or SGPT less than 2.5 times normal\*
• Alkaline phosphatase less than 2.5 times normal NOTE: \* Unless Gilbert's syndrome present
• Renal:
• Creatinine clearance greater than 50 mL/min
• Cardiovascular:
• Cardiac ejection fraction normal
• Pulmonary:
• DLCO at least 50% predicted
• FEV\_1 and FVC at least 75% predicted
• Other:
• HIV negative
• Not pregnant
• Negative pregnancy test
• No non-neoplastic disease that would preclude intensive chemotherapy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• Chemotherapy:
• See Disease Characteristics
• Endocrine therapy:
• Not specified
• Radiotherapy:
• No prior external beam radiotherapy to more than 25% of the active bone marrow
• Surgery:
• Not specified